These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21619856)

  • 41. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The evolution of safety assessments for veterinary medicinal products in the European Union.
    Woodward K
    Vet Hum Toxicol; 2004 Aug; 46(4):199-205. PubMed ID: 15303395
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Complying with US and European change control requirements, Part I.
    Donawa ME
    Med Device Technol; 1997 Oct; 8(8):10-3. PubMed ID: 10174270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of genotoxicity of herbal medicinal products: a co-ordinated approach.
    Kelber O; Steinhoff B; Kraft K;
    Phytomedicine; 2012 Mar; 19(5):472-6. PubMed ID: 22301069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of user safety, exposure and risk to veterinary medicinal products in the European Union.
    Woodward KN
    Regul Toxicol Pharmacol; 2008 Feb; 50(1):114-28. PubMed ID: 18060673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cause and measure of short of quality control on Chinese medicine herbs].
    Chen J; Chen L; An Z; Yu X; Zhan Y
    Zhong Yao Cai; 2003 Jan; 26(1):43-6. PubMed ID: 12858774
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [RAPD techniques and quality standards of Chinese materia medica].
    Zhu H; Zhou C; Teng J; Jin W
    Zhong Yao Cai; 2003 Jan; 26(1):61-4. PubMed ID: 12956181
    [No Abstract]   [Full Text] [Related]  

  • 49. Risk assessment strategies for Europe: integrated safety strategy or final product control: Example of Listeria monocytogenes in processed products from pork meat industry.
    Salvat G; Fravalo P
    Dtsch Tierarztl Wochenschr; 2004 Aug; 111(8):331-4. PubMed ID: 15469063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modern European monographs for quality control of Chinese herbs.
    Bauer R; Franz G
    Planta Med; 2010 Dec; 76(17):2004-11. PubMed ID: 21077026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monitoring veterinary vaccines for contaminating viruses.
    Ottiger HP
    Dev Biol (Basel); 2006; 126():309-19; discussion 327. PubMed ID: 17058507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Applying the new medical collateral EMC standard EN60601-1-2:2001.
    Bearpark J
    Med Device Technol; 2005 Sep; 16(7):24-5. PubMed ID: 16259156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A unique issue in the standardization of Chinese materia medica: processing.
    Zhao Z; Liang Z; Chan K; Lu G; Lee EL; Chen H; Li L
    Planta Med; 2010 Dec; 76(17):1975-86. PubMed ID: 21049396
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety.
    Coppens P; da Silva MF; Pettman S
    Toxicology; 2006 Apr; 221(1):59-74. PubMed ID: 16469424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. European regulations relevant to the marketing and use of fish vaccines.
    Lee A
    Dev Biol Stand; 1997; 90():341-6. PubMed ID: 9270862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
    [No Abstract]   [Full Text] [Related]  

  • 57. [European Agency for the Evaluation of Medicinal Products: five years experience].
    Sauer F
    Bull Mem Acad R Med Belg; 2000; 155(5-6):254-8; discussion 259-62. PubMed ID: 11304960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between nature and source of risk and process validation.
    Berthold W; Werz W; Walter JK
    Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
    [No Abstract]   [Full Text] [Related]  

  • 59. Should Anthroposophic Medicinal Products Be Regulated in Europe?
    Michaux G
    Eur J Health Law; 2017 Mar; 24(1):46-66. PubMed ID: 29210253
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Excipients: regulatory aspects].
    Artiges A
    Therapie; 1999; 54(1):15-9. PubMed ID: 10216417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.